header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-28454
Fish name: nz117Tg
Genotype: nz117Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by nz117Tg
Human Disease Conditions Citations
inflammatory bowel disease chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Wang et al., 2015
GENE EXPRESSION
Gene expression in nz117Tg
RNA expression
Expressed Gene Structure Conditions Figures
cdx1b control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
csf1ra control Fig. 3 with image from Okuda et al., 2015
Fig. 1 with image from Yang et al., 2012
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
csf3r standard conditions Fig. 4 from Liongue et al., 2009
lcp1 standard conditions Fig. 4 with image from Shiau et al., 2013
lyz standard conditions Fig. 4 from Liongue et al., 2009
mir223 standard conditions Fig. 5 with image from Zhou et al., 2018
mpeg1.1 standard conditions Fig. 5 with image from Zhou et al., 2018
mpx control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
myd88 standard conditions Fig. 1Fig. 3 from Hall et al., 2009
sarm1 standard conditions Fig. 3 from Hall et al., 2009
ticam1 standard conditions Fig. 3 from Hall et al., 2009
tirap standard conditions Fig. 3 from Hall et al., 2009
vegfaa control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
vegfc control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
vegfd control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab2-lcp1 lcp1 standard conditions Fig. 4 with image from Shiau et al., 2013
PHENOTYPE
Phenotype in nz117Tg
Phenotype Conditions Figures
caudal fin neutrophil increased amount, abnormal amputation: caudal fin Fig. 6Fig. 9 from Hall et al., 2014
caudal fin neutrophil increased amount, ameliorated amputation: caudal fin, chemical treatment: PPARalpha agonist Fig. 9 from Hall et al., 2014
caudal fin neutrophil increased amount, ameliorated amputation: caudal fin, chemical treatment: matrix metalloproteinase inhibitor Fig. 6 from Hall et al., 2014
hindbrain neutrophil increased amount, abnormal chemical treatment by injection: monosodium urate Fig. 6 from Hall et al., 2018
inflammatory response increased occurrence, abnormal high cholesterol, high glucose Fig. 4 with image from Wang et al., 2013
inflammatory response increased occurrence, ameliorated high cholesterol, high glucose, chemical treatment: pioglitazone Fig. 4 with image from Wang et al., 2013
inflammatory response increased occurrence, ameliorated high cholesterol, high glucose, chemical treatment: metformin Fig. 4 with image from Wang et al., 2013
intestinal lymphatic network lymphangiogenesis increased process quality, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 4 with image from Okuda et al., 2015
intestinal lymphatic network lymphangiogenesis process quality, ameliorated chemical treatment: 2,4,6-trinitrobenzenesulfonic acid, chemical treatment: EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor Fig. 4 with image from Okuda et al., 2015
intestinal lymphatic network lymphangiogenesis process quality, ameliorated chemical treatment: sunitinib, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 4 with image from Okuda et al., 2015
intestinal lymphatic network lymphangiogenic sprout amount, ameliorated chemical treatment: sunitinib, chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 4 with image from Okuda et al., 2015
intestinal lymphatic network lymphangiogenic sprout amount, ameliorated chemical treatment: 2,4,6-trinitrobenzenesulfonic acid, chemical treatment: EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor Fig. 4 with image from Okuda et al., 2015
intestinal lymphatic network lymphangiogenic sprout increased amount, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 4 with image from Okuda et al., 2015
intestine inflammatory response increased occurrence, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 5 with image from Wang et al., 2015
intestine leukocyte increased amount, abnormal chemical treatment: tunicamycin Fig. 5 with image from Thakur et al., 2014
intestine neutrophil amount, ameliorated chemical treatment: 2,4,6-trinitrobenzenesulfonic acid, chemical treatment: mesalamine Fig. S2 with image from Okuda et al., 2015
intestine neutrophil increased amount, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 5 with image from Wang et al., 2015
intestine neutrophil increased amount, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. S2 with image from Okuda et al., 2015
macrophage aggregated, abnormal chemical treatment: tunicamycin Fig. 5 with image from Thakur et al., 2014
myeloid cell accumulation caudal vein, abnormal high cholesterol, high glucose Fig. 4 with image from Wang et al., 2013
myeloid cell accumulation caudal vein, ameliorated high cholesterol, high glucose, chemical treatment: metformin Fig. 4 with image from Wang et al., 2013
myeloid cell accumulation caudal vein, ameliorated high cholesterol, high glucose, chemical treatment: pioglitazone Fig. 4 with image from Wang et al., 2013
neutrophil vegfc expression decreased amount, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
response to bacterium process quality, normal standard conditions Fig. 3 with image from Thakur et al., 2014

CITATIONS  (36)